Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | BPTF | Q12830 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5312699 | 1.00 | ATM (0.48) | ATMGAAL3MBTL1MEN1KMT2A | |
| SCHEMBL5315426 | 1.00 | ATM (0.48) | ATMGAAL3MBTL1MEN1KMT2A | |
| SCHEMBL2184936 | 0.98 | ATM (0.50) | ATMGAAL3MBTL1MEN1KMT2A | |
| SCHEMBL31011078 | 0.88 | — | — | |
| Pyridine SCHEMBL28153398 | 0.84 | HTT (0.42) | L3MBTL1MEN1KMT2ATDP1ALDH1A1 | |
| SCHEMBL28191935 | 0.81 | CA2 (0.46) | ATMMEN1KMT2ADPP4LMNA | |
| Piperazine SCHEMBL28191934 | 0.79 | CA2 (0.44) | ATMMEN1KMT2ADPP4LMNA | |
| SCHEMBL27396631 | 0.79 | ATM (0.50) | ATMGAAL3MBTL1MEN1KMT2A | |
| SCHEMBL6886932 | 0.78 | CYP1A2 (0.46) | KMT2ATDP1SMN1; SMN2HTT | |
| SCHEMBL10337221 | 0.78 | ATM (0.56) | ATMGAAL3MBTL1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2346507-A1 | USE OF QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF VIRAL DISEASES | Boehringer Ingelheim International GmbH (DE) | 2011-07-27 | — | — | EP | claimed |
| US-20100075966-A1 | Substituted Dihydroimidazoles and their Use in the Treatment of Tumors | NOVARTIS AG | 2010-03-25 | — | — | US | claimed |
| WO-2010026029-A1 | USE OF QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF VIRAL DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-03-11 | — | — | WO | claimed |
| EP-2097386-A2 | SUBSTITUTED DIHYDROIMIDAZOLES AND THEIR USE IN THE TREATMENT OF TUMORS | Novartis AG (CH) | 2009-09-09 | — | — | EP | claimed |
| WO-2008065068-A2 | SUBSTITUTED DIHYDROIMIDAZOLES AND THEIR USE IN THE TREATMENT OF TUMORS | NOVARTIS AG (CH) | 2008-06-05 | — | — | WO | claimed |
| EP-1592426-B1 | 2-CYANOPYRROLOPYRIMIDINES AND PHARMACEUTICAL USES THEREOF | NOVARTIS AG (CH) | 2007-12-19 | — | — | EP | claimed |
| US-20060247251-A1 | 2-Cyanopyrrolopyrimidines and pharmaceutical uses thereof | NOVARTIS AG (CH) | 2006-11-02 | — | — | US | claimed |
| EP-1592426-A1 | 2-CYANOPYRROLOPYRIMIDINES AND PHARMACEUTICAL USES THEREOF | Novartis AG (CH) | 2005-11-09 | — | — | EP | claimed |
| WO-2004069256-A1 | 2-CYANOPYRROLOPYRIMIDINES AND PHARMACEUTICAL USES THEREOF | NOVARTIS AG (CH) | 2004-08-19 | — | — | WO | claimed |
| US-5665719-A | Benzoxazinone and benzopyrimidinone piperidinyl tocolytic oxytocin receptor antagonists | MERCK & CO., INC. (US) | 1997-09-09 | — | — | US | claimed |
| EP-4230624-A1 | QUINAZOLINE-2,4-DIAMINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING SAME AS ACTIVE INGREDIENT | The Asan Foundation (KR) | 2023-08-23 | — | — | EP | disclosed |
| EP-3357943-B1 | MODIFIED CONJUGATED DIENE-BASED POLYMER AND METHOD OF PREPARING THE SAME | LG CHEMICAL LTD (KR) | 2022-07-20 | — | — | EP | disclosed |
| US-11130758-B2 | Tetrahydropyrazolopyrimidine compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2021-09-28 | — | — | US | disclosed |
| CN-108473621-B | Modifier, modified conjugated diene polymer and preparation method thereof | 株式会社LG化学 | 2021-01-12 | — | — | CN | disclosed |
| US-10450387-B2 | Modifier, modified and conjugated diene-based polymer and methods for preparing them | LG CHEM, LTD. (KR) | 2019-10-22 | — | — | US | disclosed |
| EP-1592426-B1 | 2-CYANOPYRROLOPYRIMIDINES AND PHARMACEUTICAL USES THEREOF | NOVARTIS AG (CH) | 2007-12-19 | — | — | EP | disclosed |
| US-20060247251-A1 | 2-Cyanopyrrolopyrimidines and pharmaceutical uses thereof | NOVARTIS AG (CH) | 2006-11-02 | — | — | US | disclosed |
| EP-1592426-A1 | 2-CYANOPYRROLOPYRIMIDINES AND PHARMACEUTICAL USES THEREOF | Novartis AG (CH) | 2005-11-09 | — | — | EP | disclosed |
| WO-2004069256-A1 | 2-CYANOPYRROLOPYRIMIDINES AND PHARMACEUTICAL USES THEREOF | NOVARTIS AG (CH) | 2004-08-19 | — | — | WO | disclosed |
| US-3941795-A | ANTIHISTAMINE, ANTIALLERGY, BRONCHODILATOR | RICHARDSON-MERRELL INC. (US) | 1976-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247251-A1 | 2-Cyanopyrrolopyrimidines and pharmaceutical uses thereof | DPYD, P2RY1, P2RY2 | ATM 4103/4885GAA 4157/4885L3MBTL1 3629/4885 |
| US-10450387-B2 | Modifier, modified and conjugated diene-based polymer and methods for preparing them | UFM1, F13A1, ITGAM | ATM 3156/4885GAA 3229/4885L3MBTL1 3716/4885 |
| US-20100075966-A1 | Substituted Dihydroimidazoles and their Use in the Treatment of Tumors | TP53, KRAS, NRAS | ATM 3428/4885GAA 3533/4885L3MBTL1 2840/4885 |
| US-11130758-B2 | Tetrahydropyrazolopyrimidine compounds | SSB, TLR8, TLR9 | ATM 903/4885GAA 2945/4885L3MBTL1 4112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.